Skip to main content

From the helm: Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer

Jessica Amir
February 5, 2021

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer.

Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC’s US journey gathers momentum with USFDA approval looming. The US is home to the world’s largest nuclear medicine market.

In this video James discusses:

  • (0:31) What CYC does & its “imminent” entry into the US
  • (1:11) Key catalysts to drive share price growth – (1:47) Commercialising the product in the US
  • (2:46) CYC’s product being endorsed to help fight COVID-19 in the US – (3:31) How the company has reduced its risks
  • (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

Morning Bell 4 October

Grady Wulff
October 4, 2022

Closing Bell 3 October

Grady Wulff
October 3, 2022

Morning Bell 3 October

Grady Wulff
October 3, 2022

Weekly Wrap 30 September

Grady Wulff
September 30, 2022

Morning Bell 30 September

Sophia Mavridis
September 30, 2022

Closing Bell 29 September

Grady Wulff
September 29, 2022

Morning Bell 29 September

Grady Wulff
September 29, 2022

Morning Bell 28 September

Grady Wulff
September 28, 2022

Closing Bell 27 September

Sophia Mavridis
September 27, 2022

Morning Bell 27 September

Sophia Mavridis
September 27, 2022

Closing Bell 26 September

Grady Wulff
September 26, 2022

Morning Bell 26 September

Grady Wulff
September 26, 2022